The study assesses the effect of a further 3 years adjuvant treatment with anastrozole vs. an untreated control group after initial 5 years of adjuvant hormone-therapy.

Inclusion Criteria:

• No disease recurrence at time of randomization,
• patients with breast cancer after surgery,
• 5 years (+/- 12 months) of prior endocrine therapy

Exclusion Criteria:

• Premenopausal patients,
• unknown or negative receptor status,
• Secondary malignant tumor